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ABSTRACT 
Context: Pheochromocytomas and paragangliomas (pheo/pgl) are neuroendocrine tumors 
derived from chromaffin cells. Although mostly benign, up to 26% of pheo/pgl will undergo 
malignant transformation. Reliable histological signs to differentiate benign pheo/pgl from 
malignant tumors are currently lacking. Increased IGF-1R expression has been shown during 
progression to metastatic phenotypes of several types of cancer. Objective: to analyze the 
distribution and expression of the IGF-1R in pheo/pgl of different genetic origin and degree of 
malignancy. Measurements: we studied the expression of the IGF-1R protein by 
immunohistochemistry, in 40 primary tumors from patients with pheo/pgl from different genetic 
etiology (11/29 metastatic/non-metastatic disease). Results: We found a strong association 
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between increased expression of IGF-1R and malignant behavior regardless the age at diagnosis 
and the genetic etiology. IGF-1R labeling was mostly weak in primary tumors from patients 
with non-metastatic pheo/pgl. Conversely, intense IGF-1R labeling was predominant in cases of 
pheo/pgl with confirmed metastatic disease. The risk of metastases was 11.7 times higher if 
tumor IGF-1R labeling was intense independently of age at diagnosis. The probability of 
remaining free of metastases was higher in patients with pheo/pgl scored weak for IGF-1R at 60 
months and more than two fold higher at 120 months of follow-up than in patients with intense 
IGF-1R labeling in their primary tumors. Conclusions: Our results strongly suggest that IGF-1R 
is associated with malignancy in familial pheo/pgl and that IGF-1R expression in the primary 
tumor might be a useful tool to detect those patients harboring pheo/pgl that have an increased 
risk of metastasis.  
 
INTRODUCTION 
Pheochromocytomas (pheo), that derive from chromaffin cells in the adrenal medulla, and 
paragangliomas (pgl), that arise from extra-adrenal chromaffin tissue, are tumors that 
synthesize, store, metabolize and secrete catecholamines.  
For a long time pheo/pgl were considered mostly as sporadic tumors, and hereditary in only 
about 10% of patients 1. Familial pheo/pgl can appear as part of the Multiple Endocrine 
Neoplasia type 2 syndrome (MEN2) A or B, caused by mutations of the protooncogen RET 2; 
the von Hippel-Lindau disease (VHL), caused by mutations of the suppressor VHL gene 3; or 
more rarely, neurofibromatosis type I 4. Also, the appearance of pheo/pgl has been described in 
another neuroendocrine related disease, the Familial neck and head Paraganglioma, caused by 
mutations at the D , B, A and C subunits of the succinate dehydrogenase (SDHD, SDHB, SDHA 
and SDHC) 5. More recently, germline mutations of the novel transmembrane-encoding gene 
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FP/TMEM127, SDHAF2, KIF1B beta and MAX genes have been described in familial and 
sporadic pheo/pgl 6-9. 
Although mostly benign, up to 26% of pheo/pgl tumors have been reported as malignant10. 
Malignancy in pheo/pgl is assessed based on the appearance of distant metastasis where the 
chromaffin tissue is normally absent 11. The greater risk of malignancy has been reported in 
extra-adrenal sympathetic pgl 10.  Moreover, SDHB-related sympathetic pgl has shown to bear 
the highest risk for malignancy, representing more than 50% of malignant pheo/pgl reported 12. 
Several arguments are in favor of an implication of epithelial-mesenchymal transition (EMT) in 
pheochromocytoma and paraganglioma malignancy. EMT is a physiologic process that 
normally contributes to the development of the embryo and may contribute to the development 
of certain pathological conditions such as fibrosis and cancer13. A recent study also revealed that 
EMT is specifically induced in succinate dehydrogenase subunit B (SDHB)-related metastatic 
tumors 14. 
 
Insulin-like growth factors 1 and 2 (IGF-1 and IGF-2) are insulin related polypeptides that play 
an important role in both, regulation of cell proliferation and inhibition of programmed cell 
death15. Alterations in the expression of IGF-1 and IGF-2 and their type 1 receptor (IGF-1R) in 
tumor cells as well as their relevance in tumor growth have been demonstrated in different 
cancer types. Using a murine pheochromocytoma cell line (MPC cells) and a Liver-IGF-1-
Deficient (LID) mouse model that has a 75% reduction in circulating IGF-1 levels, we have 
recently provided insight into the critical role of the IGF-1/IGF-1R circuit in maintaining tumor 
phenotype and survival of already transformed pheochromocytoma cells and its requirement for 
the initial establishment of these tumors16. 
Increased IGF-1R expression has been shown during progression to metastatic phenotypes of 
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several types of cancer15. The role of the IGF family ligands, has also been shown in some 
experimental models with regard to the induction of EMT. Recently, it was also shown that 
constitutively active IGF-1R causes cell transformation and EMT in a normal epithelial breast 
cell line, which is significant, as relatively few oncogenes, when expressed alone, have been 
shown to cause in vivo tumorigenic potential in MCF10A cells17. 
 
Based on these evidences, we hypothesize that IGF-1R expression is higher in malignant 
compared to benign familial pheo/pgl. To test this hypothesis, we analyzed, by 
immunohistochemistry, the expression of IGF-1R in primary tumors from patients harboring 
pheo/pgl of different genetic origin and degree of malignancy. 
 
PATIENTS AND METHODS 
Experimental Design: We performed a cohort study in a tertiary pediatric hospital in Buenos Aires, 
Argentina. Eligible patients were all index cases with a diagnosis of pheo/pgl referred to the Centro 
de Investigaciones Endocrinológicas, Hospital de Niños Ricardo Gutiérrez, from January 1985 to 
December 2011, from whom paraffin embedded tissue from primary tumors was available for 
immunohistochemistry and clinical charts with follow-up after the diagnosis were accessible. 
Exclusion criteria were insufficient or low quality tumor tissue in the paraffin blocks, and diagnosis of 
metastasis not confirmed by scintigraphy or histology.  
The protocol was approved by the Ethical Committee of the Hospital de Niños Ricardo 
Gutiérrez, and conducted according to the Ethical Principles for Medical Research Involving 
Human Subjects of the World Medical Association Declaration of Helsinki. Patients, parents 
or legal guardians were informed, and signed an informed consent.  
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Exposure and outcome measures: Intensity of IGF-1R immunohistochemical labeling was scored as 
weak when the staining was more intense than that of the normal adrenal medulla but less intense 
than that of the normal adrenal cortex processed on the same slide, or as intense when it was 
similar to that observed in the normal adrenal cortex processed on the same slide, in at least one 
area. 
Malignant disease was defined as the presence of pheo/pgl at sites distant from the primary tumor 
where the chromaffin tissue is normally absent, according to the World Heath Organization 18. All 
other cases were considered as benign, including patients with recurrences, defined as the 
reappearance of disease in the former primary tumor localization, after complete tumor eradication 
and normalization of biochemical tests. 
 
Data sources: Clinical records were examined to obtain standard demographic data and information 
on presenting signs and symptoms, metastatic disease or recurrences. The diagnosis of pheo/pgl was 
made on the basis of laboratory determinations of urinary and/or plasma catecholamines and their 
metabolites19 and confirmed by histology after surgery. No patient underwent cortex-sparing 
surgery. Follow-up was performed annually, involving physical examination and urinary 
catecholamine measurements. Diagnosis of metastasis or recurrences was ascertained in the 
presence of the biochemical and clinical features by imaging and functional studies (scintigraphy) for 
localization and histological confirmation. Hepatic metastases were always confirmed by histology.  
Samples from the primary tumors were evaluated for IGF-1R labeling by 2 observers blinded 
to the clinical diagnosis, and given an alphanumeric code to assure patient’s confidentiality. 
For each sample, tumor immunohistochemistry was compared in the same slide with normal 
adrenal tissue obtained from autopsy within 3 hours after death to avoid overt autolysis and 
deterioration of immunoreactivity and/or receptor protein. 
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IGF-1R Immunohistochemistry: Tumor samples were fixed in 10% neutral formaldehyde and 
paraffin embedded; 5-μm thick sections were stained with hematoxilin and eosin. Each slice of 
tumor was mounted on charged glass slides along with normal adrenal tissue, as an internal control 
and for comparative purposes. Sections were dewaxed in xylene, rehydrated, and endogenous 
peroxidase blocked with 3% H2O2. Antigen retrieval was carried out in a microwave oven for 3 min in 
0.01 M (pH = 6.0) citrate buffer. Nonspecific binding was blocked with Tris-buffered saline containing 
1% bovine serum albumin. The rabbit polyclonal primary antibody against the IGF-1R (1:500 in Tris-
buffered saline) was from Santa Cruz (Santa Cruz, CA, USA)20. Antibody-antigen binding was detected 
using appropriate biotinylated secondary antibodies followed by addition of peroxidase-conjugated 
streptavidin (Ready-to-use streptavidin-peroxidase LSAB+System-HRP DAKO, Carpinteria, CA, USA). 
Sites of peroxidase activity were demonstrated using 3,3'-diaminobenzidine (Liquid DAB+, DAKO, 
Carpinteria, CA, USA). Slides were counterstained with hematoxylin for 30 sec. The cellular 
distribution of IGF-1R was assessed using an optic microscope.  
 
IGF-1R RNA expression analyses. Total RNA from snap frozen tissues conserved at -80°C  
corresponding to tumors classified by immunohistochemistry as weak (n=6) or intense (n=5) for IGF-
1R labeling was isolated using the Trizol reagent (Invitrogen Life Technologies,CA,USA) according to 
the manufacturer’s protocol and digested with DNase (Qiagen, Hilden, Germany).  Complementary 
DNA (cDNA) was synthesized using a reaction mixture containing 1 µg of total RNA, random 
hexamers  and the MMLV reverse transcriptase (Invitrogen Life Technologies,CA,USA), following the 
procedure suggested by the manufacturer. Negative controls omitting the RNA or the reverse 
transcriptase were included and tested in the PCR procedure. Complementary DNA of all 11 
specimens were subjected to quantitative Real time PCR assays (qRT-PCR) using EvaGreen as 
intercalating dye. The qRT-PCR was performed in a Rotor Gene 6000 cycler. In all cases, experiments 
were done in duplicate. Negative controls for cDNA synthesis and PCR procedures were included in 
all cases. Primer specificity: a Rotor-Gene 6000 melting curve analysis was performed, which for both 
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primer sets resulted in single product-specific melting curves. Gel electrophoresis and a melting 
curve analysis of PCR products showed that no primer-dimers were generated during the runs. The 
levels of IGF-1R were studied and β-actin was selected as housekeeping gene. The total expression 
ratio of IGF-1R was tested for significance by a randomization test implemented in the relative 
expression software tool (REST) (www.gene-quantification.info)21, which is an Excel-based 
application for group wise comparison and statistical analysis of relative expression results in qRT-
PCR. The corresponding qRT-PCR efficiency for each gene was determined with the slope of a linear 
regression model, according to the equation: E = 10[–1/slope].  
 
Genetic studies: Genetic studies were performed to determine the presence of mutations in von 
Hippel-Lindau (VHL), ret proto-oncogene (RET) and succinate dehydrogenase subunits B and D (SDHB 
and SDHD) genes. VHL, RET, SDHB and SDHD genes were amplified from genomic DNA of peripheral 
blood cells. DNA was isolated by the SDS proteinase K method. The regions encoding for exon 1, 2, 
and 3 of the VHL gene, 10, 11, 13, 14, 15 and 16 of the RET proto-oncogene, 1 to 8 of the SDHB gene, 
and 1 to 4 of the SDHD gene were amplified by PCR using sets of specific primers. To characterize the 
point mutations, nucleotide sequences of PCR products were analyzed using direct sequencing ABI 
3700 fluorescence sequencer (Applied Biosystems). Sequences results were analyzed by direct 
comparison with reference sequences or by the use of the Mutation Surveyor software. Appropriate 
positive and negative controls were included. No gross deletions were tested for the VHL gene. 
 
Statistical Analysis: Sample size calculation was performed to establish the least number of 
specimens to be evaluated in order to detect a difference in the proportion of cases with malignant 
evolution between intense and weak IGF-1R labeling. Using a bilateral test, a sample size of 9 
specimens per group was considered sufficient to detect a difference with a 99% confidence level 
and a 90% power, based on an estimated proportion of 10% malignancy evidenced at 5 yr of follow-
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up in cases with weak labeling and 90% malignancy in cases with intense labeling.  For categorical 
variables, cross tabulations were analyzed using the Χ2 test when applicable. Otherwise, the Fisher’s 
Exact Test was chosen. Kaplan Meier survival plots were constructed to determine whether the 
expression of IGF-1R influenced tumor metastasis. Log rank (Cox Mantel) test was applied to 
compare survival functions. Cox regression analysis was used to adjust for confounders such as age 
at diagnosis or genetic diagnosis (VHL, MEN2, SDH or none), and validated by the Maximum 
Likelihood Test. All p-values were two sided and probabilities less than 0.05 were considered 
significant. SPSS 18.0 software (SPSS, Chicago, IL, USA) was used for all statistical analysis. 
 
RESULTS 
Forty specimens, corresponding to 40 patients with a median age at diagnosis of 16 years (range 4-70 
years) were analyzed. Sixteen patients harbored VHL disease, 10 had familial SDH mutation-related 
tumors (9 SDHB and 1 SDHD) and 8 MEN 2 (6 MEN2A and 2 MEN2B). The remaining 6 patients had 
negative genetic studies.  Malignant disease was confirmed in 11 of the 40 patients. In 3 out of 40 
patients recurrences were documented.  
Table 1 shows individual demographic features of all 40 patients: genetic etiology, gender, age 
at diagnosis, tumor localization, presence and location of metastasis, recurrences, time to 
metastasis or recurrences, time of follow-up (months), survival status and IGF-1R score. 
IGF-1R expression was assessed by immunohistochemistry in the 40 specimens, all of which showed a 
diffuse positive labeling (Figure 1). Panel A shows a representative microphotograph of a tumor with an 
intense labeling, similar to that observed in the normal adrenal gland cortex (panel C, c). Panels B shows 
a tumor with weak labeling, similar to that observed in the normal medulla (panels C and D, m). Also 
IGF-1R expression was analyzed by qRT-PCR in the 11 specimens from which snap frozen tissue was 
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available. There was a 2.35-fold increase in the relative expression of IGF-1R (p<0.05) in intense tumors 
(n=5) compared to weak tumors (n=6), reinforcing the immunohistochemistry score. 
The distribution of the IGF-1R labeling of all 40 processed specimens according to the 
diagnosis of metastatic or non-metastatic disease is summarized in Table 2. IGF-1R labeling 
was mostly weak in primary tumors from patients with non-metastatic pheo/pgl. Conversely, 
intense IGF-1R labeling was predominant in cases of pheo/pgl with confirmed metastatic 
disease (Pearson χ2 8.976, p=0.004). Time free of metastases was longer in patients harboring 
tumors with weak IGF-1R labeling (267 months, 95% CI 228 - 306) than in patients with tumors 
showing intense IGF-1R labeling (107 months, 95% CI 66-148, Mantel-Cox Log rank test 8.91,  
p = 0.003, Figure 2). Also, the probability of remaining free of metastases was higher in patients 
with pheo/pgl scored weak for IGF-1R at 60 months and more than two fold higher at 120 
months of follow-up [absolute risk 0.91 (95%CI 0.74-1.000) ] than in patients with intense IGF-
1R labeling in their primary tumors [absolute risk 0.59 (95% CI 0.37 - 0.81) and 0.39 (95% CI 
0.13-0.67), respectively].The risk of metastases was 11.7 times higher if tumor IGF-1R labeling 
was intense (Hazard Ratio11.7 95%IC 1.59-91.9, p = 0.019) independently of age at diagnosis 
(Cox regression). 
Diagnostic sensitivity of intense IGF-1R labeling for metastatic disease was 0.91 (10/11 
patients) while specificity was 0.62 (18/29 patients without metastatic disease). 
Analysis of IGF-1R expression according to the genetic etiology showed an intense IGF-1R labeling in 
specimens from all 9 patients with SDHB mutation-related tumors. Five of them, with 5 or more years 
of follow-up, had documented metastases. Two of these patients died from causes related to the 
pheo. In contrast, tumors from patients with VHL disease were mostly weak (8 out of 13) for IGF-1R 
labeling and benign. In this group, only 1 out of 5 patients with intense IGF-1R labeling in the tumor 
had pgl and metastatic disease. For MEN2, 2 out of 8 patients had tumors with an intense IGF-1R 
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labeling and presented metastatic disease. Of the remaining 6 tumors that showed a weak labeling for 
IGF-1R, all but one were from patients with non-metastatic disease. 
Four tumors from patients with negative genetic tests were intense for IGF-1R labeling, and two of 
these patients had metastatic disease and died from causes related to the pheo. 
All 3 patients with recurrent pheo, belonged to the VHL group; 2 patients had tumors with weak IGF-
1R labeling and one of them died (case #15) from causes unrelated to the pheo. The third case (case 
#4) had a tumor with intense IGF-1R labeling and died from causes related to the pheo. 
 
DISCUSSION 
Our data show that intense IGF-1R labeling in primary pheo/pgl was associated with almost 12 fold 
increased risk of metastases, regardless the age at diagnosis and genetic background. As already 
reported, malignancy was more frequently found in tumors from SDHB patients. Conversely, weak IGF-
1R labeling was more prevalent in tumors from VHL patients, who showed a more benign outcome. 
Although increased expression of the IGF-1R has been associated with worse prognosis in several 
types of cancer, some reports have shown otherwise, in particular regarding breast and prostate 
cancer22;23, where a decreased expression of the IGF-1R is observed in malignant lesions compared to 
the normal epithelium. Recently, it has been showed that the IGF-1R expression in benign human pheo 
cells is higher than in normal adrenal medulla 24. The present study is the first to report a significant 
overexpression of the IGF-1R in primary human pheo/pgl with malignant behavior compared to benign 
tumors. In our series, 10 out of 11 tumors from patients with documented metastases showed an 
intense IGF-1R labeling.  Moreover, a worse outcome of pheo/pgl patients was associated with intense 
IGF-1R expression levels as is shown by Kaplan Meier analysis. Conversely, patients with weak IGF-1R 
tumor labeling have 1.5 times the probability to remain free of metastasis at 5 years after surgery than 
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those with intense IGF-1R tumor labeling and more than twice this probability at 10 years after 
surgery.  
At present the only treatment for pheo/pgl is surgery. Besides, there are no histological features to 
definitively identify or predict the outcome of pheo/pgl patients. Malignant behavior can be currently 
defined only by the appearance of metastasis. Several markers, such as COX and Bcl2, MIB-1, p53, 
VEGF and SNAIL among others 25-29, or histological features (PASS score) 30 have been proposed as 
potential predictors of malignancy of pheo/pgl, but results have been inconclusive. For example, SNAIL 
expression had a 100% sensitivity of detecting the malignant tumors. However, by this method, the 
specificity was only 56%. A recent report 31 proposed methoxytyramine as a new biomarker of 
metastatic pheochromocytoma and paraganglioma, with a calculated diagnostic sensitivity of only 
57%, but with a specificity of 85%. In our study, IGF-1R expression had 91% sensitivity of detecting 
malignant tumors, while the specificity was 62%. While the majority of cases have a long follow-up 
period, there are some with only short follow-up. Thus, the absence of malignancy in these cases 
cannot be taken for granted. However, this bias would tend to decrease the difference in the 
proportion of intense labeling between malignant and benign cases and to decrease the diagnostic 
specificity. In fact, in 6 of 10 cases with high intensity and no documented metastases, the follow-up is 
less than 5 yr. A longer follow-up eventually detecting more malignant cases would increase the 
proportion of true positives. Therefore, our analysis is conservative and does not overestimate our 
conclusions. 
One limitation of this study is that our series has a large proportion of young patients, probably due to 
the fact that familial cases usually present at younger ages. However, it should be noted that our 
patients were all index cases that guided the familial studies and not selected from screening 
programs. Furthermore, we used a Cox regression analysis to adjust for age at diagnosis, which 
allowed us to rule out the age at diagnosis as a confounding variable in the analysis. Another 
peculiarity of our study is the high proportion of malignant cases in patients with MEN2, probably due 
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to a disproportionate referral of patients with metastases to our center. Since our objective was not to 
estimate the prevalence of malignancy in subjects with MEN2, our sample of MEN2 patients was small 
(8 cases), thus inadequate to make such estimation.  
 
Overexpression of IGF-1R promotes neoplastic growth 32 and absence of the IGF-IR has been shown to 
prevent malignant transformation 33. IGF-1R expression is regulated by a variety of factors, including 
tumor suppressor genes, transcription factors and other growth factors. VHL protein can inhibit the 
activity and the expression of the IGF-1R in normal or tumoral renal cell lines 34;35. VHL and SDHB/D 
inactivation both result in Hypoxia Inducible Factors deregulation 36, leading to the activation of the 
hypoxic response, even in normoxic conditions. Although some patients harboring mutations in VHL 
and SDHB/D develop pheo/pgl, there are significant clinical differences as well as different patterns of 
gene expression between these two groups of patients37. Mutations of the SDH subunits are 
associated with a higher incidence of extra-adrenal pheo, and malignancy is frequent in SDHB but rare 
in VHL associated pheo12.  Accordingly, in our group of patients with SDH mutations tumors were 
mostly extra-adrenal, malignant and were associated with an intense labeling for the IGF-1R, and 
tumors from our group of VHL patients were mostly benign and had a positive weak staining for the 
IGF-1R. The mechanisms responsible for enhanced IGF-1R expression in pheo/pgl associated to 
hereditary syndromes and other malignancies are still unclear. Overexpression of the IGF-1R in our 
group of pheo/pgl was related to malignancy irrespective of the genetic etiology. This suggests that 
mechanisms other than those related to the development of pheo/pgl in these syndromes are 
responsible for the higher expression of the IGF-1R in the subset of malignant tumors.  
 
Our results strongly suggest that immunolabeling for the IGF-1R is associated with malignancy in 
familial pheo/pgl and might be a useful tool to predict the adverse outcome of pheo/pgl patients. 
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Furthermore, although future research is needed, our work supports the IGF-1/IGF-1R circuit as an 
attractive molecular target for the treatment of malignant pheo/pgl.  
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FIGURE LEGENDS 
Figure 1: Immunostaining for IGF-1R in benign and malignant pheo/pgl. Paraffin embedded 
tumor biopsies were processed for IHC, along with normal adrenal gland, using a specific 
antibody against IGF-1R. (A) Representative malignant tumor showing intense labeling for 
IGF-1R similar to the adrenal cortex (c) showed on control tissue depicted on (D). Benign 
tumors (B) showed weak labeling for the IGF-1R comparable to that observed in normal adrenal 
medulla (m in C and D). c. adrenal cortex; m: adrenal medulla. 
 
Figure 2: Time free of metastasis in patients with pheo/pgl according to the IGF-1R labeling in 
their primary tumors. W: Weak IGF-1R labeling; I: Intense IGF-1R labeling. Censored: a 
“Censored” case is a patient that did not have the event (metastasis) until the last recorded time 
of follow-up (indicated with a vertical dash). 
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Table 1: Demographic data of pheo/pgl patients. 
Patie
nt 
case 
Genetic 
Etiology 
Gend
er 
Age at 
diagnos
is 
Locati
on 
Met R
ec 
Time 
to 
Met/R
ec 
Follow up 
months 
Status IGF-
1R 
score 
1 VHL M 4 A B No No  144 Alive W 
2 VHL M  6 A B No Yes 96 172 Alive W 
3 VHL F 7 A U No No  60 Alive I 
4 VHL F 7 A B No Yes 48 60 D 
(Tumor) 
I 
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5 VHL M 8 A B No No  288 Alive W 
6 VHL  M 9 A B No No  60 Alive W 
7 VHL F 12 A U No No  54 Alive I 
8 VHL M 12 A B No No  48 Alive I 
9 VHL M 14 A B No No  238 Alive W 
10 VHL M 14 A U No No  36 Alive W 
11 VHL F 15 A  U No No  36 Alive W 
12 VHL F 16 A U No No  108 Alive I 
13 VHL M 24 A U No No  48 Alive W 
14 VHL M 29 A B No No  60 Alive W 
15 VHL F 47 A B No yes 24 96 D* W 
16 VHL M 70 PGL Yes No 72 72 D(Tumor
) 
I 
17 SDHB M 8 A B Yes No 48 96 Alive I 
18 SDHB M 10 PGL No No  108 Alive I 
19 SDHB F 13 PGL No No  108 Alive I 
20 SDHB M 14 PGL No No  36 Alive I 
21 SDHB F 14 PGL Yes No 6 84 Alive I 
22 SDHB F 16 PGL No No  30 Alive I 
23 SDHB F 38 PGL Yes No 24 120 D 
(Tumor) 
I 
24 SDHB F 45 PGL Yes No 30 96 Alive I 
25 SDHB F 47 PGL Yes No 9 96 D 
(Tumor) 
I 
26 SDHD M 28 PGL   No No  120 Alive W 
27 MEN 2A F 25 A  B No No  120 Alive W 
28 MEN 2A M 25 A  U Yes No 60 264 Alive W 
29 MEN 2A F 27 A  B No No  132 Alive W 
30 MEN 2A F 32 A  B Yes No 74 156 Alive I 
31 MEN 2A F 43 A  B No No  36 Alive W 
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32 MEN 2A M 50 A  B No No  48 Alive W 
33 MEN 2B M 26 A  B No No  48 Alive W 
34 MEN 2B M 42 A  B Yes No 48 48 D** I 
35 Neg F 12 PGL Yes No 24 132 D 
(Tumor) 
I 
36 Neg F 13 PGL No No  24 Alive I 
37 Neg F 13 A U No No  204 Alive I 
38 Neg F 32 A  U No No  36 Alive W 
39 Neg F 33 A  U  Yes No 12 204 D 
(Tumor) 
I 
40 Neg F 64 A  U No No  36 Alive W 
 
M: male; F: Female; Met: Metastasis; Rec: Recurrences D: Dead.  *Death unrelated to the 
tumor (Pancreatic Tumor) ** Death immediately after surgery.  
Location: A; Adrenal, B: Bilateral; U: unilateral; PGL: extraadrenal paraganglioma. 
IGF-1R score: I: Intense; W: weak. 
 
Table 2: Distribution of IGF-1R labeling in primary tumors 
 from patients with pheo/pgl according to malignancy. 
Pheo/pgl Weak Intense
Non-metastatic 62.1 % (18/29)a 37.9 % (11/29)
Metastatic 9.1% (1/11) 90.9 % (10/11)
   a: p value <0.01  Χ2 =8.561.  
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